RESEARCH

Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. Tasman Oncology Research is a well-resourced and well-published clinical trials unit; with a team of five clinical trial-coordinators and two data entry staff with their their own dedicated suite next to the day infusion unit.

CLINICAL TRIALS

Why do we participate in clinical trials?

Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. All trial related consultations and procedures are provided at no cost to the patient. All research conducted by the Tasman Oncology Research is conducted in accordance with applicable regulatory requirements and the internationally recognised standards of Good Clinical Practice.

Through our close partnerships with clinical research organisations, we coordinate a number of Phase One, Two and Three multi-site international clinical trials which are outlined on the Current Clinical Trials page

If you would like more information regarding clinical trial opportunities, please speak with your doctor or one of our research coordinators. The coordinators can be reached directly on (07) 5613 2484, or research@tasmanhealthcare.com.au.

RESEARCH FACILITIES

Tasman Oncology Research brings together an experienced team of research coordinators, nurses, data managers and scientists to support an advanced clinical trial unit.

Our clinical trials unit is staffed by a highly qualified group of research coordinators who are certified in Good Clinical Practice through ARCS Australia and also hold IATA certification for the transportation of dangerous goods. All coordinators have extensive experience using IVRS/IWRS and eCRF systems. We have a dedicated Quality Manager on team ensuring compliance with ICH-GCP guidelines, TGA regulations, sponsor requirements, protocol requirements and Tasman Health Care SOPs. We have a strong working relationship with Bellberry HREC for efficient study start-up timelines and lead site responsibilities.

Staff are familiar and have up-to-date training in several eCRF platforms including InForm, Medidata RAVE, Oracle RDC and eClinical OS. They are collectively experienced in using patient electronic diaries and imaging transfer software including AGMedNet and Bioclinica.
In addition, the research coordinators have laboratory experience and are competent in all aspects of specimen collection, preparation, handling and shipping.

Tasman Oncology Research views continual education and training as a key investment strategy. Therefore we ensure staff are qualified to perform procedures through ongoing training and professional development. All investigators, sub-investigators and clinical research staff attend both internal and external compulsory training, as well as undertaking further education specific to the nature of this work.

Our monthly quality meetings monitor the need for training and Clinical Research staff conduct regular in-services on the requirements and conduct of clinical research. In particular the specific requirements of individual studies for staff from other departments involved in the conduct of clinical research.

CURRENTLY RECRUITING CLINICAL TRIALS

Please speak to your treating oncologist or GP to investigate whether there may be any current clinical trials you may be suitable for. The following clinical trials are currently open for recruitment:

CA224-020

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.
 clinicaltrials.gov/ct2/show/NCT01968109

MASTERKEY-115

A phase 2, open-label, single-arm, multicenter clinical trial designed to evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting

MK3475-02A

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02A

The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.

https://clinicaltrials.gov/ct2/show/NCT04305041

 

MK3475-02B

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02B

The goal of substudy 02B is to evaluate the safety and efficacy of investigational treatment arms in participants with 1L advanced melanoma and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/pembrolizumab monotherapy.

https://clinicaltrials.gov/ct2/show/NCT04305054

 

MK3475-02C

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02C

The goal of substudy 02C is to evaluate the safety and efficacy of investigational treatment arms in participants with Stage III melanoma who are candidates for neoadjuvant therapy to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.

https://clinicaltrials.gov/ct2/show/NCT04303169

There are currently no specific trials currently recruiting for this cancer type

There are currently no specific trials currently recruiting for this cancer type

There are currently no specific trials currently recruiting for this cancer type

MK7339-007

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

https://clinicaltrials.gov/ct2/show/NCT04123366

TVEC 318

A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)

https://clinicaltrials.gov/ct2/show/NCT02509507

CA2209-650

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02985957 

There are currently no specific trials currently recruiting for this cancer type

TACTI-002

A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)

https://clinicaltrials.gov/ct2/show/NCT03625323

RPL-002-18

A Randomized, Controlled, Open-label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination with RP1 in Patients with Advanced Cutaneous Squamous Cell Carcinoma

There are currently no specific trials currently recruiting for this cancer type

Please contact our research rooms on (07) 5613 2484 for further information, or follow the clinicaltrials.gov hyperlink for each particular study.